Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Marketed as Vyrologix, leronlimab is an investigational humanised immunoglobulin G4 monoclonal antibody that hinders C-C chemokine receptor type 5 (CCR5).
Product Name : Vyrologix
Product Type : Antibody
Upfront Cash : Inapplicable
May 27, 2021
Lead Product(s) : Leronlimab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lupin and Biomm Enter into a Distribution and Marketing Agreement for Pegfilgrastim in Brazil
Details : Under the terms of agreement, Biomm will distribute and market biosimilar Pegfilgrastim in Brazil. Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy.
Product Name : Lupifil-P
Product Type : Protein
Upfront Cash : Undisclosed
March 12, 2021
Lead Product(s) : Pegfilgrastim
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Agreement